Prosecution Insights
Last updated: April 19, 2026

Examiner: KRETZER, KYLE W.

Tech Center 3700 • Art Units: 3774 3791

This examiner grants 62% of resolved cases

Performance Statistics

61.8%
Allow Rate
-8.2% vs TC avg
212
Total Applications
+47.3%
Interview Lift
1297
Avg Prosecution Days
Based on 157 resolved cases, 2023–2026

Rejection Statute Breakdown

13.3%
§101 Eligibility
16.8%
§102 Novelty
38.6%
§103 Obviousness
27.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18598983 METHODS FOR ASSESSING SLEEP CONDITIONS Final Rejection Apple Inc.
17008101 ADJUSTING SETTINGS TO DIFFERENT DEGREES OF AGGRESSIVENESS IN AN AUTOMATED INSULIN DELIVERY SYSTEM BASED ON QUALITY OF BLOOD GLUCOSE LEVEL CONTROL BY A USER Non-Final OA Insulet Corporation
18693749 BIOPSY NEEDLE ACCESSORY Non-Final OA The Johns Hopkins University
18210980 Techniques For Tracking Ingestible Device Final Rejection THE REGENTS OF THE UNIVERSITY OF MICHIGAN
18316708 GLUCOSE SENSOR Final Rejection Medtronic MiniMed, Inc.
18027391 ABRASION PROTECTED MICRONEEDLE AND INDWELLING EAB SENSORS Non-Final OA University Of Cincinnati
18147755 SYSTEMS AND METHODS FOR ANALYTE MONITORING Final Rejection ABBOTT DIABETES CARE INC.
18314368 APPARATUS INCLUDING HOUSING, POWER SOURCE, AND COUPLER Non-Final OA Senseonics, Incorporated
19041712 THYROID FUNCTION MONITORING METHOD ACCORDING TO MEDICATION, AND MONITORING SERVER AND USER TERMINAL PERFORMING THE SAME Non-Final OA THYROSCOPE INC.
18581062 THYROID FUNCTION MONITORING METHOD ACCORDING TO MEDICATION, AND MONITORING SERVER AND USER TERMINAL PERFORMING THE SAME Final Rejection THYROSCOPE INC.
18315858 METHOD FOR PRODUCING AN ANALYTE SENSOR, AN ANALYTE SENSOR, AND A USE THEREOF Final Rejection Roche Diabetes Care, Inc.
18307071 ANALYTE SENSOR SYSTEM AND A METHOD FOR ITS PRODUCING Final Rejection Roche Diabetes Care, Inc.
18294564 A DEVICE FOR NON-INVASIVE MONITORING Non-Final OA Teknologian tutkimuskeskus VTT Oy
17416683 TECHNIQUES FOR STIMULATION ARTEFACT ELIMINATION Non-Final OA Cochlear Limited
18523301 ESC EVALUATION METHOD Non-Final OA Withings
18644043 SYSTEMS AND METHODS FOR DETECTING NERVE FUNCTION Non-Final OA SafeOp Surgical, Inc.
18595932 ENHANCED DETECTION AND ANALYSIS OF BIOLOGICAL ACOUSTIC SIGNALS Final Rejection Entac Medical, Inc.
18210688 Cloud Analysis System for Sport and Health Final Rejection Decentralized Biotechnology Intelligence Co., Ltd.
18577473 SYSTEM AND METHOD FOR NON-INVASIVE MEASUREMENT OF GLYCATED HEMOGLOBIN Non-Final OA KOREA I.T.S. CO., LTD.
18570900 METHOD AND SYSTEM FOR OBTAINING MEASUREMENT OF COGNITIVE PERFORMANCE Non-Final OA Altoida, Inc.
18534802 SYSTEM AND METHOD FOR POSTURE CORRECTION EXERCISE RECOMMENDATION OF ARTIFICIAL INTELLIGENCE BY USING WEARABLE DEVICE Non-Final OA PostureAI Inc.
18554491 SYSTEM, METHOD AND COMPUTER PROGRAM FOR MONITORING HEALTH OF A PERSON Non-Final OA MERU HEALTH OY
18553733 WIRED IMPLANTABLE MULTIANALYTE MONOLITHIC INTEGRATED SENSOR CIRCUIT Non-Final OA Integrated Medical Sensors, Inc.
18470631 Teeth Cleaning Systems with Integrated Sensors for Reliable Detection of Analytes in Saliva Non-Final OA Feno Labs, Inc.
18277724 BIOMARKER FOR PREDICTION OF CHEMOTHERAPY-INDUCED NEUROPATHY Non-Final OA VIBROSENSE DYNAMICS AB
17730741 SYSTEMS AND METHODS FOR BLOOD GLUCOSE MANAGEMENT USING CONCENTRATED INSULIN Non-Final OA Pacific Diabetes Technologies Inc
18208211 APPARATUSES, SYSTEMS, AND METHODS OF CONTROLLING SENSOR DEPLOYMENT Final Rejection DexCorn, Inc.
18313713 CONTINUOUS HEALTH MONITORING SYSTEM Final Rejection Indigo Diabetes NV
17183921 CONTINUOUS HEALTH MONITORING SYSTEM Final Rejection Indigo Diabetes NV
17993432 SYSTEM AND METHOD FOR DETERMINING INTOXICANT IMPAIRMENT Non-Final OA Bloonics Holding B.V.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month